

Drug Monograph

Drug/Drug **Differin[®] (adapalene) 0.3% Topical Gel / Retinoid Agent**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each 1 gram of Differin[®] 0.3% topical gel contains 3 mg of adapalene.

Manufacturer: DPT Laboratories, Ltd. San Antonio, TX 78215

Indications: Differin[®] 0.3% topical gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.

Costs: \$ 237.45 per 45 gram tube of Differin[®] 0.3% topical gel. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List and is a non-preferred agent.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Non-Preferred Agent
 Appropriate Indications PA Required

Prepared By: Skander Yalaoui, Pharm. D. Candidate

Date: July 17, 2012